STAAR Surgical

STAA · NASDAQ

$22.32+$0.44 (+2.01%)TodayMarket closed ·
Prev close $21.88

Latest news

  • Press releaseBusiness Wire

    STAAR Surgical Names Andrew Pilon as Vice President of Business Development

  • NewsPriya Nigam

    STAAR Surgical Analyst Turns Bullish On Potential For ‘Meaningful’ Street Upside

  • NewsAvi Kapoor

    CarMax Posts Upbeat Q2 Earnings, Joins Iovance Biotherapeutics, Perella Weinberg Partners And Other Big Stocks Moving Higher On Tuesday

  • Press releaseBusiness Wire

    STAAR Surgical Board Approves $50 Million Share Repurchase Authorization

  • Press releasePRNewswire

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA).

  • Press releaseBusiness Wire

    STAAR Surgical Releases Landmark Global Report Showing Structural Multi-Market Shift Toward Lens-Based Vision Correction

  • Press releaseBusiness Wire

    STAAR Surgical Names Former CEO David Bailey as Chief Commercial Officer

  • News

    Staar Surgical Q2 EPS $0.16 Beats $0.15 Estimate, Sales $93.535M Beat $90.589M Estimate

  • Press releaseBusiness Wire

    STAAR Surgical Reports Second Quarter 2026 Results

  • Press releaseBusiness Wire

    STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer

  • Press releaseBusiness Wire

    STAAR Surgical to Host Second Quarter 2026 Earnings Results Call and Webcast on August 12, 2026

  • NewsVandana Singh

    Caution Lingers for STAAR Surgical Amid Middle East Geopolitical Tensions

  • NewsAvi Kapoor

    Intuitive Surgical, Netflix And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

  • News

    12 Health Care Stocks Moving In Thursday's After-Market Session

  • News

    STAAR Surgical Reports Q2 Preliminary Net Sales To Be Over $90M

  • Press releaseBusiness Wire

    STAAR Surgical Announces Preliminary Net Sales for Second Quarter 2026

  • Press releaseBusiness Wire

    STAAR Surgical Announces Participation in Upcoming Investor Conferences

  • News

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseBusiness Wire

    STAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder Letter

  • Press releaseBusiness Wire

    STAAR Surgical to Host First Quarter 2026 Earnings Results Call and Webcast on May 13, 2026

  • NewsAvi Kapoor

    Crude Oil Surges 3%; Neogen Shares Fall After Q3 Results

  • News

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Press releaseBusiness Wire

    STAAR Surgical Announces Preliminary Net Sales for First Quarter 2026

  • News

    A Glimpse Into The Expert Outlook On Staar Surgical Through 7 Analysts

  • Press releaseBusiness Wire

    STAAR Surgical Issues Shareholder Letter

  • Press releaseBusiness Wire

    STAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 Results

  • Press releaseBusiness Wire

    STAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision Correction

  • Press releaseBusiness Wire

    STAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026

  • NewsVandana Singh

    FDA Expands Approval For Staar Surgical's Popular Implantable Lens

  • Press releaseBusiness Wire

    FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction

  • Press releaseBusiness Wire

    STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs

  • News

    Assessing Staar Surgical: Insights From 4 Financial Analysts

  • Press releaseBusiness Wire

    STAAR Surgical and Broadwood Partners Enter Into Cooperation Agreement

  • Press releaseBusiness Wire

    Alcon Terminates Agreement to Acquire STAAR Surgical

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.